RCT: Ravidasvir plus sofosbuvir are effective and well tolerated in patients with chronic HCV infection, with potential as an affordable treatment for these patients18 Apr, 2021 | 21:19h | UTC
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial – The Lancet Gastroenterology & Hepatology
Commentary on Twitter
Ravidasvir + sofosbuvir has the potential to provide an additional affordable, simple, and efficacious #publichealth tool to eliminate HCV.
— Drugs for Neglected Diseases initiative (@DNDi) April 16, 2021